Summit Therapeutics Receives 'Moderate Buy' Rating from Analysts

The biotech company's stock has a consensus target price of $29.83 among brokers covering the firm.

Mar. 31, 2026 at 8:25am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking financial machinery and equipment in muted industrial tones, conveying a sense of institutional power and economic security.Summit Therapeutics' stock has received a 'Moderate Buy' rating from analysts, reflecting mixed views on the biotech firm's prospects.Summit Today

Summit Therapeutics PLC (NASDAQ:SMMT) has received an average rating of 'Moderate Buy' from the 17 research firms currently covering the company, according to Marketbeat Ratings. The stock has a consensus 12-month price target of $29.83 among analysts who have updated their coverage in the last year.

Why it matters

Summit Therapeutics is a clinical-stage biotech company focused on developing precision medicines for serious and life-threatening diseases. The 'Moderate Buy' rating and price target from analysts suggest they see potential upside in the company's stock, despite some mixed views on the company's prospects.

The details

The 17 research firms covering Summit Therapeutics have provided the following ratings: 2 sell recommendations, 5 hold recommendations, 8 buy recommendations, and 2 strong buy recommendations. Several analysts have issued recent reports on the stock, with Piper Sandler setting a $40 price target and Truist Financial upgrading the stock to 'strong buy'.

  • Summit Therapeutics reported its latest quarterly earnings on February 23, 2026.

The players

Summit Therapeutics PLC

A clinical-stage biotechnology company dedicated to developing precision medicines for serious and life-threatening diseases.

Citizens Jmp

A research firm that reaffirmed a 'market outperform' rating and $40 price target on Summit Therapeutics.

Piper Sandler

A research firm that set a $40 price target on Summit Therapeutics.

Truist Financial

A research firm that upgraded Summit Therapeutics to a 'strong-buy' rating.

Zacks Research

A research firm that upgraded Summit Therapeutics from a 'strong sell' to a 'hold' rating.

HC Wainwright

A research firm that lowered its price target on Summit Therapeutics from $40 to $30 and maintained a 'buy' rating.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Summit Therapeutics can meet or exceed analysts' earnings expectations when the company reports its next quarterly results.

The takeaway

The 'Moderate Buy' rating and $29.83 average price target from analysts suggest they see potential upside in Summit Therapeutics' stock, despite some mixed views on the company's prospects. The biotech firm's ability to advance its pipeline of precision medicines will be key to driving future growth.